Arming an Oncolytic Herpes Simplex Virus Type 1 With a Single Chain Fragment Variable Antibody Against PD-1 for Experimental Glioblastoma Therapy.
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2311
Full Text
Open PDFAbstract
Available in full text
Date
October 2, 2018
Authors
Publisher
American Association for Cancer Research (AACR)